Insulet (PODD) Tops Q4 EPS by 9c, Revenues Beat; Offers Q1 Revenue Mid-Point Guidance Below Consensus, FY19 Revenue Views Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Insulet (PODD) Tops Q4 EPS by 9c, Revenues Beat; Offers Q1 Revenue Mid-Point Guidance Below Consensus, FY19 Revenue Views Below Consensus

Insulet Reports Fourth Quarter 2018 Revenue of $164.9 Million, Up 26% Year-Over-Year, and Full Year 2018 Revenue of $563.8 Million, Up 22%

February 25, 2019 4:01 PM EST

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months and full year ended December 31, 2018.

Fourth Quarter Financial Highlights:

Fourth quarter 2018 revenue of $164.9 million, up 26% compared to $130.5 million in the prior year, exceeds guidance of $159 to $164 million... More